SCHEMBL6006279

SCHEMBL6006279

Cc1ccc(S(=O)(=O)OCCC(c2ccccc2)c2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.46
ACHE P22303 2/20 0.42
ALDH1A1 P00352 1/20 0.42
HSD11B1 P28845 1/20 0.42
BCHE P06276 1/20 0.42
EEF2K O00418 1/20 0.41
CCR5 P51681 1/20 0.40
LMNA P02545 3/20 0.38
MAPT P10636 2/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ACP3 P15309 1/20 0.38
P2RX7 Q99572 1/20 0.38
CYP2D6 P10635 3/20 0.38
CYP2C19 P33261 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
MAPK1 P28482 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4655851 0.88 LMNA (0.44) ACHEALDH1A1BCHELMNAL3MBTL1
SCHEMBL4667569 0.86 GAA (0.46) PTGS2ACHEALDH1A1HSD11B1BCHE
SCHEMBL6007086 0.85 PARL (0.40) ALDH1A1LMNAHTTCNR1
SCHEMBL3646001 0.82 ALDH1A1 (0.46) ACHEALDH1A1BCHELMNAHTT
SCHEMBL7840144 0.79 ALDH1A1 (0.43) ACHEALDH1A1BCHELMNAL3MBTL1
SCHEMBL9666817 0.78 CYP24A1 (0.43) ALDH1A1LMNAHTTCNR1SIGMAR1
SCHEMBL6006289 0.78 CYP2D6 (0.46) ACHEALDH1A1HSD11B1BCHEEEF2K
SCHEMBL18092988 0.78 ALDH1A1 (0.45) ALDH1A1LMNAL3MBTL1CYP1A2CYP3A4
SCHEMBL18092987 0.78 ALDH1A1 (0.45) ALDH1A1LMNAL3MBTL1CYP1A2CYP3A4
SCHEMBL15000821 0.77 ALDH1A1 (0.54) PTGS2ACHEALDH1A1BCHELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060287298-A1 Pharmaceutical for treatment of neurological and neuropsychiatric disorders ALLELIX NEUROSCIENCE INC. 2006-12-21 US disclosed
EP-1014966-B1 PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS ALLELIX NEUROSCIENCE INC (US) 2006-08-02 EP disclosed
US-7019024-B2 Pharmaceutical for treatment of neurological and neuropsychiatric disorders ALLELIX NEUROSCIENCE INC. (US) 2006-03-28 US disclosed
US-6191165-B1 ANTIDEPRESSANTS; SCHIZOPHRENIA; ALZHEIMER'S DISEASE; ANTIEPILEPTIC AGENTS ALLELIX NEUROSCIENCE INC. 2001-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287298-A1 Pharmaceutical for treatment of neurological and neuropsychiatric disorders SLC18A2, SLC6A1, SLC6A11 PTGS2 1335/4885ACHE 35/4885ALDH1A1 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.